LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Kodu・Aktsiate loetelu・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Suletud

SektorTervishoid

3.14 1.95

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

3.16

Põhinäitajad
By Trading Economics
Sissetulek	-15M -40M
Müük	8.2M 50M
Kasumimarginaal	-80.43
Töötajad	435
EBITDA	-19M -42M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+29.87% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	214M 1.3B
Eelmine avamishind	1.19
Eelmine sulgemishind	3.14

Uudiste sentiment

By Acuity

50%

133 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

2.02 / 2.115 Toetus ja vastupanu

Maravai LifeSciences Holdings Inc (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15. märts 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15. märts 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15. märts 2026, 22:37 UTC

Market Talk

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15. märts 2026, 22:18 UTC

Market Talk

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 03:00 UTC

Uudisväärsed sündmused

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Iran War Delivers Windfall to America's Oil Country -- WSJ

14. märts 2026, 02:03 UTC

Tulu

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14. märts 2026, 01:32 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14. märts 2026, 00:29 UTC

Omandamised, ülevõtmised, äriostud

13D Filings -- Barrons.com

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Maravai LifeSciences Holdings Inc (Class A) Prognoos

Hinnasiht

By TipRanks

29.87% tõus

12 kuu keskmine prognoos

Keskmine 4 USD 29.87%

Kõrge 5 USD

Madal 3 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Maravai LifeSciences Holdings Inc (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Maravai LifeSciences Holdings Inc (Class A) aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.02 / 2.115Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

133 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.